GO:0043308 eosinophil degranulation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043308 eosinophil degranulation is the regulated exocytosis of secretory granules containing preformed mediators such as major basic protein, eosinophil peroxidase, and eosinophil cationic protein by an eosinophil.
• Degranulation can occur through classical granule exocytosis, piecemeal degranulation, or cytolytic release, and the mode used shapes the tissue outcome.
• Eosinophil degranulation is not only a host-defense effector function; it is also detected in normal human tissues such as the gastrointestinal tract.
• Dysregulated degranulation contributes to asthma, eosinophilic skin diseases, and psoriatic skin inflammation linked to intestinal changes.
• Key granule proteins include MBP1 (PRG2), EPX, ECP (RNASE3), and EPO, while surface receptors such as TLR7 and lipid mediators such as lysophosphatidylserine modulate release.
• CRISPR knockout, knock-in, and overexpression models allow causal testing of candidate genes in eosinophil degranulation pathways.
Description
Eosinophil degranulation (GO:0043308) is the regulated exocytosis of secretory granules containing preformed mediators such as major basic protein, eosinophil peroxidase, and eosinophil cationic protein by an eosinophil. This biological process is central to eosinophil effector function because it converts intracellular stores of cytotoxic and immunomodulatory proteins into extracellular signals that act on pathogens, epithelial cells, nerves, and immune cells. Researchers study GO:0043308 because its intensity, location, and mode of release determine whether eosinophils protect the host or drive tissue damage in allergic and inflammatory disease. The process is not a single uniform event. Eosinophils can release granule contents through classical exocytosis, piecemeal degranulation, or cytolytic mechanisms, and these routes differ in speed, membrane requirements, and the spectrum of released mediators. Degranulation has been observed even in normal human tissues, including the gastrointestinal tract, indicating that it is part of baseline eosinophil biology rather than only a pathological response. At the same time, excessive or misdirected degranulation is associated with asthma mucus plug formation, eosinophilic skin diseases, and psoriatic skin inflammation with small intestinal inflammatory changes. Because eosinophil degranulation sits at the intersection of allergy, immunity, and tissue remodeling, it is a high-value target for mechanistic studies. Modern research combines receptor-level triggers, granule protein trafficking, and CRISPR-based perturbation to define which genes are causally required for release. This article summarizes the QuickGO definition, the major molecular players, disease links, and experimental methods used to investigate GO:0043308.
eosinophil degranulation At A Glance
| GO ID | GO:0043308 |
|---|---|
| GO term | eosinophil degranulation |
| Ontology | biological_process |
| Synonym | eosinophil granule exocytosis |
| Definition | The regulated exocytosis of secretory granules containing preformed mediators such as major basic protein, eosinophil peroxidase, and eosinophil cationic protein by an eosinophil. |
| Major function | Release of preformed granule mediators from eosinophils to act on pathogens, epithelial cells, nerves, and immune cells. |
| Cellular context | Eosinophil secretory granules, plasma membrane, and cytoskeletal machinery. |
| Release modes | Classical exocytosis, piecemeal degranulation, and cytolytic release. |
| Physiological detection | Detected in normal human tissues including the gastrointestinal tract. |
| Disease relevance | Asthma, eosinophilic skin diseases, and psoriatic skin inflammation with intestinal changes. |
What Is GO:0043308?
In my own words, GO:0043308 eosinophil degranulation is the regulated exocytosis of secretory granules containing preformed mediators such as major basic protein, eosinophil peroxidase, and eosinophil cationic protein by an eosinophil. The term covers the controlled fusion of granule membranes with the plasma membrane or with intracellular compartments, leading to release of granule contents. It is a biological process that depends on granule biogenesis, cytoskeletal rearrangement, and receptor-proximal signaling, and it can proceed through multiple morphological modes including classical exocytosis, piecemeal degranulation, and cytolytic release.
Why Is eosinophil degranulation Important in Cell Biology?
Eosinophil degranulation matters because it is the principal mechanism by which eosinophils deliver cytotoxic and immunomodulatory proteins to the extracellular space, and the balance between appropriate and excessive release determines host defense versus tissue injury. Understanding GO:0043308 helps explain why eosinophil-rich diseases such as asthma and eosinophilic dermatoses cause structural damage, and it identifies molecular checkpoints that could be targeted therapeutically.
• Defines the effector output of eosinophils by controlling release of major basic protein, eosinophil peroxidase, and eosinophil cationic protein.
• Occurs in normal human tissues such as the gastrointestinal tract, showing it is part of baseline eosinophil biology.
• Contributes to asthma pathology, including mucus plug formation and persistence.
• Is implicated in severe asthma through lysophosphatidylserine-induced eosinophil extracellular trap formation and degranulation.
• Links psoriatic skin inflammation to small intestinal inflammatory changes via TLR7-dependent eosinophil degranulation in mice.
• Underlies eosinophilic skin diseases and eosinophilic dermatoses reviewed in clinical literature.
• Provides a mechanistic explanation for eosinophil-mediated tissue damage beyond simple cell infiltration.
• Offers candidate targets for modulating allergic and inflammatory responses.
• Can be studied with CRISPR knockout, knock-in, and overexpression models to test causal gene requirements.
• Requires integration of receptor signaling, granule trafficking, and cytoskeletal regulation for a complete mechanistic picture.
What Happens During eosinophil degranulation?
Triggering and receptor-proximal signaling
In simple terms: The eosinophil first receives a signal telling it to release its granule contents.
Eosinophil degranulation begins when surface receptors and lipid mediators engage signaling pathways that lower the threshold for granule release. Lysophosphatidylserine can induce eosinophil extracellular trap formation and degranulation, linking lipid signaling to severe asthma. In mice, TLR7-dependent eosinophil degranulation connects psoriatic skin inflammation to small intestinal inflammatory changes, demonstrating that innate immune receptor activation can drive the process. These triggers converge on intracellular calcium and kinase cascades that prepare granules for fusion.
Granule mobilization and cytoskeletal rearrangement
In simple terms: Inside the cell, granules must be moved to the right place before they can release their contents.
After triggering, secretory granules containing major basic protein, eosinophil peroxidase, and eosinophil cationic protein are mobilized along cytoskeletal tracks toward the plasma membrane or toward intracellular release sites. This step distinguishes classical exocytosis from piecemeal degranulation, in which granule contents are shuttled in vesicles rather than released by whole-granule fusion. The cytoskeletal and membrane trafficking machinery therefore determines the mode and extent of mediator release.
Membrane fusion and mediator release
In simple terms: The granule membrane fuses with the cell membrane, dumping the granule contents outside the cell.
Membrane fusion is the defining event of GO:0043308, releasing preformed mediators such as major basic protein, eosinophil peroxidase, and eosinophil cationic protein into the extracellular space. In cytolytic release, granule contents exit together with nuclear and cytoplasmic material, producing eosinophil extracellular traps. The specific mode of release influences which mediators reach the tissue and how much collateral damage occurs.
Post-release mediator actions
In simple terms: Once outside the cell, the released proteins act on nearby tissues and immune cells.
Released granule proteins act on pathogens, epithelial cells, nerves, and immune cells, and they can promote tissue remodeling and inflammation. In asthma, eosinophil degranulation products contribute to mucus plug formation and persistence. In eosinophilic skin diseases, degranulation is part of the inflammatory cascade that damages skin. In normal gastrointestinal tissue, degranulation occurs without overt disease, indicating context-dependent outcomes.
Resolution and feedback control
In simple terms: The cell eventually stops releasing granules and the process is tuned down.
Degranulation is a regulated process, and feedback mechanisms limit further release after the initial trigger. The balance between activating and inhibitory signals determines whether degranulation remains protective or becomes destructive. Because eosinophil degranulation is detected in normal tissues such as the gastrointestinal tract, baseline release is likely restrained by local regulatory cues. Dysregulation of these controls is thought to contribute to chronic eosinophilic inflammation.
Key Genes Involved in GO:0043308 eosinophil degranulation
The following genes and proteins represent the major granule components, receptors, and signaling molecules implicated in eosinophil degranulation (GO:0043308) according to the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRG2 | Encodes major basic protein, a core granule mediator released during degranulation | Marker of eosinophil granule content and release |
| EPX | Encodes eosinophil peroxidase, a granule enzyme released during degranulation | Readout of granule exocytosis and oxidative tissue damage |
| RNASE3 | Encodes eosinophil cationic protein, a granule mediator released during degranulation | Marker of eosinophil activation and degranulation |
| EPO | Encodes eosinophil peroxidase, a granule protein involved in mediator release | Target for assessing granule protein trafficking |
| TLR7 | Innate immune receptor whose activation drives eosinophil degranulation in mice | Links skin inflammation to intestinal changes |
| LYPLA1 | Enzyme involved in lysophosphatidylserine metabolism relevant to eosinophil activation | Candidate for lipid-mediated degranulation studies |
| LYPLA2 | Enzyme involved in lysophosphatidylserine metabolism relevant to eosinophil activation | Candidate for lipid-mediated degranulation studies |
| GPR34 | Receptor for lysophosphatidylserine implicated in eosinophil responses | Potential mediator of lipid-driven degranulation |
| SIGLEC8 | Eosinophil surface receptor linked to eosinophil biology | Candidate for receptor-level regulation of degranulation |
| IL5RA | Receptor for IL-5, a key eosinophil cytokine | Context for eosinophil activation and degranulation |
| CCR3 | Chemokine receptor involved in eosinophil recruitment | Upstream of tissue degranulation events |
| ITGB1 | Integrin implicated in eosinophil adhesion and granule release | Candidate for adhesion-dependent degranulation |
| RAB27A | Rab GTPase involved in secretory granule trafficking | Candidate for granule mobilization studies |
| STXBP1 | Syntaxin-binding protein implicated in membrane fusion | Candidate for fusion machinery studies |
| SNAP23 | SNARE protein involved in granule-plasma membrane fusion | Candidate for exocytosis machinery studies |
| VAMP7 | Vesicle-associated membrane protein implicated in granule release | Candidate for piecemeal degranulation studies |
| ACTB | Cytoskeletal protein required for granule mobilization | Candidate for cytoskeletal regulation studies |
| TUBB | Microtubule protein involved in granule transport | Candidate for trafficking studies |
How Is eosinophil degranulation Regulated?
Eosinophil degranulation is regulated by receptor-proximal signals, lipid mediators, and innate immune receptors. Lysophosphatidylserine can induce eosinophil extracellular trap formation and degranulation, linking lipid signaling to severe asthma. TLR7-dependent eosinophil degranulation connects psoriatic skin inflammation to small intestinal inflammatory changes in mice, showing that innate immune receptor activation is a regulatory input. The process is also subject to feedback control that limits release after triggering, and the balance between activating and inhibitory cues determines whether degranulation remains protective or becomes destructive. Because degranulation occurs in normal tissues such as the gastrointestinal tract, local regulatory cues likely restrain baseline release.
eosinophil degranulation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TLR7 | Psoriatic skin inflammation linked to small intestinal inflammatory changes | Knockout mouse or cell line to test TLR7-dependent degranulation |
| PRG2 | Asthma mucus plug formation and persistence | Knockout or knockdown to assess major basic protein release |
| EPX | Eosinophil granule-mediated tissue damage in asthma | Overexpression and knockout to measure peroxidase release |
| RNASE3 | Eosinophilic skin diseases and dermatoses | Knock-in reporter to track cationic protein release |
| GPR34 | Severe asthma via lysophosphatidylserine signaling | Point mutation or knockout to test lipid-mediated degranulation |
Asthma and airway inflammation
Eosinophil degranulation contributes to asthma pathology, including mucus plug formation and persistence. Lysophosphatidylserine-induced eosinophil extracellular trap formation and degranulation has been implicated in severe asthma, suggesting that lipid-driven release pathways are clinically relevant. These findings position GO:0043308 as a mechanistic node in airway remodeling and obstruction.
Eosinophilic skin diseases and dermatoses
Eosinophilic skin diseases are a broad group of disorders in which eosinophil infiltration and degranulation contribute to cutaneous inflammation. Eosinophilic dermatoses have been reviewed clinically, and degranulation is part of the pathogenic cascade in these conditions. In mice, TLR7-dependent eosinophil degranulation links psoriatic skin inflammation to small intestinal inflammatory changes, indicating that skin-triggered degranulation can have systemic consequences.
Normal tissue eosinophil degranulation
Eosinophil infiltration and degranulation occur in normal human tissues, including the gastrointestinal tract, providing evidence that degranulation is not exclusively pathological. This baseline release suggests that GO:0043308 has homeostatic roles that must be distinguished from disease-associated overactivation. Understanding these normal functions is important for interpreting degranulation markers in clinical samples.
From eosinophil degranulation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for eosinophil degranulation? | CRISPR knockout in eosinophil-like cell lines or primary eosinophils |
| Does a specific point mutation alter granule release? | CRISPR point mutation knock-in at the endogenous locus |
| How does a disease-associated variant affect degranulation? | Knock-in of the variant followed by degranulation assays |
| Where and when is a granule protein released? | Tagged knock-in with a fluorescent or epitope tag |
| Does overexpression of a signaling gene enhance degranulation? | CRISPR overexpression or cDNA overexpression model |
| Which genes are essential in a genome-wide screen? | CRISPR library screening with degranulation readouts |
How to Study the eosinophil degranulation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Granule protein ELISA | Release of major basic protein, eosinophil peroxidase, or eosinophil cationic protein | Quantifying degranulation in vitro and ex vivo |
| Immunohistochemistry | Tissue deposition of granule proteins | Detecting degranulation in normal and diseased tissues |
| Live-cell imaging | Granule trafficking and membrane fusion | Distinguishing classical exocytosis from piecemeal degranulation |
| RNA sequencing | Transcriptional changes during eosinophil activation | Identifying candidate regulators of degranulation |
| Proteomics | Protein content of granules and released supernatants | Defining the degranulation secretome |
| CRISPR knockout | Loss-of-function effects on degranulation | Testing causal requirement of candidate genes |
| CRISPR knock-in | Effects of specific variants or tags on degranulation | Modeling disease-associated mutations |
| CRISPR library screening | Genome-wide regulators of degranulation | Discovery of novel pathway components |
Granule release assays
Degranulation can be measured by detecting released granule proteins such as major basic protein, eosinophil peroxidase, and eosinophil cationic protein in supernatants or tissues. These assays are used to quantify the extent of GO:0043308 under different stimuli, including lysophosphatidylserine and TLR7 ligands. They are also used to compare normal versus diseased tissues, as shown for the gastrointestinal tract.
Imaging of granule trafficking and fusion
Microscopy-based methods visualize granule mobilization, membrane fusion, and cytolytic release, distinguishing classical exocytosis from piecemeal degranulation. Imaging can also detect eosinophil extracellular traps that form alongside degranulation. These approaches are essential for assigning a specific release mode to an experimental condition.
Transcriptomic and proteomic profiling
RNA sequencing and proteomics can identify genes and proteins that change during eosinophil activation and degranulation. Such profiling helps prioritize candidate regulators for functional testing. In disease contexts such as asthma, profiling of mucus plugs and eosinophilic tissues can reveal degranulation signatures.
Genetic perturbation with CRISPR
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in eosinophil degranulation. These tools can be combined with granule release assays to determine whether a gene is required, sufficient, or modulatory for GO:0043308. Library screening extends this approach to genome-wide discovery of regulators.
How CRISPR Can Be Used to Study GO:0043308 eosinophil degranulation
Knockout
CRISPR knockout is used to delete candidate genes and test whether they are required for eosinophil degranulation. For example, knocking out TLR7 or its downstream effectors can determine whether TLR7-dependent degranulation is essential in a given model. Knockout of granule protein genes such as PRG2 or EPX can reveal their contribution to release and tissue effects.
Point Mutation
CRISPR point mutation introduces precise nucleotide changes to model disease-associated variants or to disable specific protein domains. This approach can test whether a phosphorylation site or binding motif is required for granule release. Point mutation models are especially useful when complete knockout is lethal or confounded by compensatory effects.
Knock-in
CRISPR knock-in can insert tags, reporters, or disease variants at endogenous loci to study degranulation in a physiological context. Tagged knock-in of granule proteins allows real-time tracking of release. Knock-in of patient-derived variants can reveal how specific mutations alter GO:0043308.
Overexpression
CRISPR overexpression or cDNA overexpression can test whether increasing the level of a candidate gene is sufficient to enhance degranulation. This is useful for validating activating signals identified in screens. Overexpression models can also reveal dose-dependent effects on granule mobilization and release.
How EDITGENE Supports eosinophil degranulation Research
Researchers studying eosinophil degranulation-related genes often need to determine whether a candidate gene is causally involved in granule release, whether a specific variant alters function, and how the gene behaves in a physiological context. EDITGENE provides CRISPR-based cell model services that address these questions with knockout, point mutation, knock-in, overexpression, and library screening approaches.
Contact EDITGENE today to design your custom CRISPR model for eosinophil degranulation research.
Frequently Asked Questions About eosinophil degranulation
What is eosinophil degranulation?
Eosinophil degranulation (GO:0043308) is the regulated exocytosis of secretory granules containing preformed mediators such as major basic protein, eosinophil peroxidase, and eosinophil cationic protein by an eosinophil.
What is the GO ID for eosinophil degranulation?
The Gene Ontology ID for eosinophil degranulation is GO:0043308, a biological_process term.
What genes are involved in eosinophil degranulation?
Key genes include PRG2, EPX, RNASE3, EPO, TLR7, and lipid signaling components such as GPR34 and LYPLA1/LYPLA2, based on published studies.
What are the modes of eosinophil degranulation?
Eosinophils can release granule contents through classical exocytosis, piecemeal degranulation, or cytolytic release, including eosinophil extracellular trap formation.
Does eosinophil degranulation occur in normal tissues?
Yes, eosinophil infiltration and degranulation have been detected in normal human tissues, including the gastrointestinal tract.
How is eosinophil degranulation linked to asthma?
Eosinophil degranulation products contribute to asthma mucus plug formation and persistence, and lysophosphatidylserine-induced degranulation has been implicated in severe asthma.
What is the role of TLR7 in eosinophil degranulation?
TLR7-dependent eosinophil degranulation links psoriatic skin inflammation to small intestinal inflammatory changes in mice.
Which diseases involve eosinophil degranulation?
Eosinophil degranulation is implicated in asthma, eosinophilic skin diseases, eosinophilic dermatoses, and psoriatic skin inflammation with intestinal changes.
How can I study eosinophil degranulation with CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models can be combined with granule release assays to test causal gene requirements.
What methods measure eosinophil degranulation?
Common methods include granule protein ELISA, immunohistochemistry, live-cell imaging, RNA sequencing, proteomics, and CRISPR-based perturbation.
Conclusion
Eosinophil degranulation (GO:0043308) is the regulated exocytosis of secretory granules containing preformed mediators such as major basic protein, eosinophil peroxidase, and eosinophil cationic protein by an eosinophil. It is a central effector process in eosinophil biology that occurs in normal tissues and becomes pathogenic when dysregulated in asthma, eosinophilic skin diseases, and psoriatic inflammation with intestinal changes. Mechanistic studies continue to define the receptors, lipid mediators, and trafficking machinery that control release, and CRISPR-based models provide a direct way to test causal roles of candidate genes. By combining precise genetic perturbation with granule release assays and profiling, researchers can clarify how GO:0043308 contributes to health and disease.
References
- 1. Fettrelet T et al.. 2021. The Enigma of Eosinophil Degranulation.. Int J Mol Sci 22(13) PMID: 34209362
- 2. Long H et al.. 2016. Eosinophilic Skin Diseases: A Comprehensive Review.. Clin Rev Allergy Immunol 50(2):189-213 PMID: 25876839
- 3. Lee JJ et al.. 2005. Eosinophil degranulation: an evolutionary vestige or a universally destructive effector function?. Clin Exp Allergy 35(8):986-94 PMID: 16120079
- 4. Kato M et al.. 2001. Eosinophil infiltration and degranulation in normal human tissues: evidence for eosinophil degranulation in normal gastrointestinal tract.. Int Arch Allergy Immunol 125 Suppl 1:55-8 PMID: 11408775
- 5. Liegeois MA et al.. 2025. Cellular and molecular features of asthma mucus plugs provide clues about their formation and persistence.. J Clin Invest 135(6) PMID: 40091838
- 6. Kim HJ et al.. 2020. Lysophosphatidylserine induces eosinophil extracellular trap formation and degranulation: Implications in severe asthma.. Allergy 75(12):3159-3170 PMID: 32535937
- 7. Papakonstantinou E et al.. 2022. [Eosinophilic dermatoses].. Dermatologie (Heidelb) 73(12):965-972 PMID: 36380139
- 8. Kim HJ et al.. 2024. TLR7-dependent eosinophil degranulation links psoriatic skin inflammation to small intestinal inflammatory changes in mice.. Exp Mol Med 56(5):1164-1177 PMID: 38689088
